帕博利珠单抗联合化疗一线治疗晚期非鳞状非小细胞肺癌:KEYNOTE-021研究G队列长期生存数据

    Pembrolizumab With or Without Chemotherapy as First-Line Therapy for Advanced Nonsquamous NSCLC: Comments to Long-Term Overall Survival Data of Cohort G in KEYNOTE-021 Study

    /

    返回文章
    返回